Genevieve Neal-Perry, MD, PhD

Experts explain the role and safety of Bayer's elinzanetant to treat vasomotor symptoms since its approval in October 2025.

Genevieve Neal-Perry, MD, PhD, highlights that phase 4 real-world data confirm that fezolinetant significantly reduces VMS bother, particularly in high-burden groups such as Black women and patients with obesity.

In this discussion from ACOG's 75th Annual Meeting, Genevieve Neal-Perry, MD, PhD, explains how elinzanetant has impacted patients since it's approval in October 2025.

Genevieve Neal-Perry, MD, PhD, outlines unmet needs in managing vasomotor symptoms among African American women and discusses how elinzanetant (Lynkuet) may help shape more equitable care.

Genevieve Neal-Perry, MD, PhD, discusses how elinzanetant (Lynkuet) improves sleep quality and menopause-related quality of life through its dual neurokinin receptor antagonism.

Genevieve Neal-Perry, MD, PhD, explains how rapid onset of symptom relief with elinzanetant (Lynkuet) may improve patient satisfaction and adherence.

Genevieve Neal-Perry, MD, PhD, reviews the design and pooled efficacy results of the OASIS 1 and OASIS 2 trials evaluating elinzanetant (Lynkuet) for moderate to severe vasomotor symptoms.

Genevieve Neal-Perry, MD, PhD, discusses the profound impact of vasomotor symptoms on quality of life during menopause and highlights racial disparities that disproportionately affect African American women.

New neurokinin receptor antagonists such as fezolinetant and elinzanetant are reshaping treatment options for menopausal hot flashes.